"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
Acute, recurrent or chronic urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) due to susceptible organisms (usually E. coli, Klebsiella-Enterobacter, staphylococcus, Proteus mirabilis and, less frequently, Proteus vulgaris) in the absence of obstructive uropathy or foreign bodies.
Meningococcal meningitis prophylaxis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations. (The prophylactic usefulness of sulfonamides when group B or C infections are prevalent has not been proven and in closed population groups may be harmful.)
Trachoma. Inclusion conjunctivitis. Nocardiosis. Chancroid. Toxoplasmosis as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy.
Important Note: In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media.
Currently, the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides, especially in the treatment of chronic and recurrent urinary tract infections.
Wide variation in blood concentrations may result with identical doses. Blood concentrations should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood concentrations of 5 to 15 mg/100 mL may be considered therapeutically effective for most infections, with blood concentrations of 12 to 15 mg/100 mL optimal for serious infections; 20 mg/100 mL should be the maximum total sulfonamide concentration, since adverse reactions occur more frequently above this concentration.
DOSAGE AND ADMINISTRATION
The usual dosage schedules are as follows:
|Weight of Pediatric Patients |
(2 Months or Older)
|Initial Dose |
(50 to 60 mg/kg)
|Dose Morning and Evening |
Daily Thereafter (25 to 30 mg/kg)
|20 lbs||1 tablet |
|½ tablet |
|40 lbs||2 tablets |
|1 tablet |
|60 lbs||3 tablets |
|1½ tablets |
|80 lbs|| 4 tablets |
| 2 tablets |
|The maximum dose for pediatric patients should not exceed 75 mg/kg/24 hours.|
| Mild to |
| 4 tablets |
| 2 tablets |
Severe Infections: 4 tablets (2 g) initially, followed by 2 tablets (1 g) three times daily thereafter.
Tablets (pale green, scored), containing 0.5 g sulfamethoxazole † bottles of 100 (NDC 0004-0010-01). Imprint on tablets: GANTANOL (sulfamethoxazole) ® ROCHE.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Gantanol Information
- Gantanol Drug Interactions Center: sulfamethoxazole oral
- Gantanol Side Effects Center
- Gantanol FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.